… Although new inhaled antibiotics have profoundly improved respiratory diseases in cystic
fibrosis (CF) patients, … In this review, the efficacy and safety of the currently available inhaled …

… cystic fibrosis (CF) patients, however their relative efficacies are unclear. We compared the
efficacy of the inhaled antibiotics … colistin) and aztreonam lysine for inhalation (AZLI) based on …

… We conducted a meta-analysis of randomised trials to evaluate the efficacy and safety of
inhaled antibiotics in patients with stable non-cystic fibrosis (CF) bronchiectasis. …

… Inhaled antibiotics have been used for a long time in patients with cystic fibrosis but are
seldom … current clinical evidence of efficacy, adverse events, and future directions of inhaled …

… evidence to support use of inhaled antibiotics in patients with bronchiectasis not due to
cystic fibrosis. We aimed to assess the efficacy and safety of inhaled antibiotics for the long-term …

… reparative mechanisms of the airway are likely to be different in CF and NCFB, which may
impact on the relative clinical effectiveness of inhaled antibiotics in CF compared with NCFB. …

… A difference in efficacy among these inhaled antibiotics may be present, but due to the limited
… other clinical efficacy outcomes when selecting an inhaled antibiotic in treating pulmonary …

… We identified only low‐ or very low‐certainty evidence to judge the effectiveness of inhaled
antibiotics for the treatment of pulmonary exacerbations in people with cystic fibrosis. The …

… aztreonam based on data from the 2012 Cystic Fibrosis Foundation national patient registry
… efficacy, so that routine use of inhaled antibiotics in this setting is not recommended (22). …

… for inhaled antibiotics in the treatment of acute pulmonary exacerbations in patients with CF.
Aerosolized antibiotics … Additional long-term, well-controlled trials of inhaled antibiotics as …